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BPCO: il modello di una patologia respiratoria cronica
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Today COPD is the subject of both basic research
and clinical studies aimed at seeking to better de-
fine its pathogenesis, diagnosis, natural history and
therapy. Of equal importance are the pharmaco -
economic studies that carry out a cost/benefit
analysis of all the measures necessary to control the
disease at the different stages of its evolution.
In the early sixties the interest of pneumologists and
microbiologists was focused on chronic bronchitis,
the first of the bronchial diseases in which, thanks
to antibiotics, subjects managed to overcome sever-
al episodes of acute lower respiratory tract infec-
tions and survive. Subsequently the definition of
COPD expanded to include other broncho -
pulmonary pathologic conditions, such as emphy-
sema, bronchiectasis and chronic asthma, charac-
terized by chronic evolution.
Today the control of all these pathologies is global
and standardized following the recommendations
of guidelines, consensus conferences or papers and
other national and international documents.
The first important step in COPD prevention is the
control of air pollution – particularly in large cen-
ters and metropolitan areas – and the reduction of
indoor pollutants combined with the campaign
against tobacco smoking and all toxic fumes, in-
cluding those of occupational origin, in diverse en-
vironments. Here, the epidemiological data provid-
ed by health authorities are of fundamental impor-
tance (attention should be paid to the diagnosis of
COPD as the main disease!) in order to know which
metropolitan areas are the most affected and investi-
gate the cause.
Last but not least comes the patient.
An early diagnosis of the disease is of fundamental
importance. Some steps need to be rigorously fol-
lowed in order to improve the course of the disease:
early diagnosis should be accompanied by an accu-
rate definition of the clinical and functional disease
status; follow up is necessary to verify the effect of
prescribed drugs as well as of other therapeutic
measures; assessment and control of complications
requires careful management carried out, if needed,
in hospital.
What methodology should be used? Medical edu-
cation and regular postgraduate courses for GPs,
who represent the front line in the control of all dis-
eases and in screening of the general population. 
Of course, when the GP first comes to suspect the
disease, he should refer the patient to the specialist
to have the diagnosis confirmed and to define the
patient’s clinical and functional status. After receiv-
ing recommendations on the therapeutic course to
follow, the GP should follow the patient to observe
the effect of drugs and verify the results: in any case
he should submit the patient to specialist control.
Careful follow up on the part of the GP and subse-
quent specialist assistance makes it possible to
monitor the natural history of the disease in the sin-
gle patient and, if necessary, take appropriate meas-
ures. Also the eventual hospital admission in the ad-
vanced stages of the disease, when home treatment
is no longer possible, must take place as soon as
possible.
COPD cannot be cured: it is possible, however, to
modify its natural history by means of prompt and
efficacious therapeutic measures. This goal will be
reached when there is a full collaboration existing
between patient, GP, specialist, laboratory and hos-
pital centers.
Not all patients respond to different therapies in the
same way. Hopefully, while waiting for pharma-
cogenomics to indicate for us the real “non respon-
ders” to different treatments, on the basis of com-
mon sense it is advisable to use what is currently
available in the most appropriate way according to
the stage of the disease: i.e. drugs belonging to dif-
ferent classes, physiotherapy, oxygen therapy, etc. If
interventions are early and appropriate, it is obvious
that there will be an economic benefit also for the
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community as a whole, considering the growing in-
cidence of COPD in the general population and the
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